Auro Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 530233 | NSE: | Pharmaceuticals & Drugs | Small Cap

Auro Laboratories Share Price

161.15 3.65 2.32%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Auro Laboratories

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Auro Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
13.96
Market Cap:
100.4 Cr.
52-wk low:
52.5
52-wk high:
178

Is Auro Laboratories Ltd an attractive stock to invest in?

1. Is Auro Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Auro Laboratories Ltd is a average quality company.

2. Is Auro Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Auro Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Auro Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Auro Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Auro Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Auro Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 8.4%8%8%6.5%19.6%18.5%15.4%25.2%7.5%5.7%-
Value Creation
Index
-0.4-0.4-0.4-0.50.40.30.10.8-0.5-0.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 33.732.727.935.540.846.843.854.350.952.955
Sales YoY Gr.--3.2%-14.5%27.1%15%14.8%-6.5%23.9%-6.2%4%-
Adj EPS 1.31.110.85.26.15.510.93.7311.5
YoY Gr.--17.1%-3.7%-24.3%561.5%18%-9%96.2%-65.7%-20.1%-
BVPS (₹) 11.112.413.815.120.827.934.545.950.654.963.8
Adj Net
Profit
0.80.70.60.53.23.83.56.82.31.97
Cash Flow from Ops. 4.5-0.87.95.94.86.99.312.8-6.63.3-
Debt/CF from Ops. 3.3-211.61.71.91.20.30.3-2.12-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.1%5.3%6.5%4%
Adj EPS 9.8%-10.4%-18.7%-20.1%
BVPS19.5%21.4%16.7%8.5%
Share Price 38.5% 22.1% 24.6% 198%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
12.29.27.95.428.72517.727.17.75.719.5
Op. Profit
Mgn %
9.291012.515.614.914.320.79.18.319.3
Net Profit
Mgn %
2.42.12.31.47.98.17.912.54.63.513.1
Debt to
Equity
2.12.11.51.10.70.50.20.10.40.2-
Working Cap
Days
16917318812411911211287139202119
Cash Conv.
Cycle
7593913929373920588466

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 19.50%

Sales growth has been subdued in last 3 years 6.50%

Net Profit has been subdued in last 3 years -18.67%

Sales growth is not so good in last 4 quarters at -2.87%

Latest Financials - Auro Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 11.5 -
TTM Sales (₹ Cr.) 55.1 -
BVPS (₹.) 63.8 -
Reserves (₹ Cr.) 34 -
P/BV 2.53 -
PE 13.96 -
From the Market
52 Week Low / High (₹) 52.50 / 178.00
All Time Low / High (₹) 0.70 / 195.00
Market Cap (₹ Cr.) 100
Equity (₹ Cr.) 6.2
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Auro Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Auro Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales34332835414744545153
Operating Expenses 31302531344038434649
Manufacturing Costs2223333434
Material Costs25231822252924293336
Employee Cost 2223333444
Other Costs 2233456766
Operating Profit 33346761154
Operating Profit Margin (%) 8.2%9.0%10.0%12.5%15.6%14.9%14.3%20.7%9.1%8.3%
Other Income 0001111111
Interest 2221111011
Depreciation 1111111111
Exceptional Items 0000000000
Profit Before Tax 11135661143
Tax 0002122311
Profit After Tax 1111444732
PAT Margin (%) 1.7%2.5%3.2%2.3%8.7%9.4%9.3%13.2%5.6%4.6%
Adjusted EPS (₹)0.91.31.41.35.77.16.511.54.63.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 7899131721293234
Share Capital 6666666666
Reserves 112371115222528
Minority Interest0000000000
Debt141613109833136
Long Term Debt78710653222
Short Term Debt79503401124
Trade Payables44455556511
Others Liabilities 1113333554
Total Liabilities 27292627303332425556

Fixed Assets

Gross Block15151520212324242525
Accumulated Depreciation56678910111213
Net Fixed Assets1110913131514141413
CWIP 0130100048
Investments 0000000000
Inventories86411343412
Trade Receivables485889671412
Cash Equivalents 101124615122
Others Assets3434432479
Total Assets 27292627303332425556

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 4-18657913-73
PBT 11135661143
Adjustment 2222222122
Changes in Working Capital 2-452-1-121-12-2
Tax Paid 000-1-100000
Cash Flow From Investing Activity -1-1-2-2-2-3-2-4-5-5
Capex -1-1-30-2-2-10-5-4
Net Investments 0000000000
Others 000-20-2-2-3-1-1
Cash Flow From Financing Activity -31-5-4-2-2-6010-8
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -100-10-1-1001
Interest Paid -1-2-2-1-1-1-10-1-1
Dividend Paid 0000000000
Others -12-4-2-10-4011-8
Net Cash Flow 1-1001229-2-10
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)8.7611.0110.839.0631.5328.9520.8428.679.477.43
ROCE (%)9.410.7611.2120.2428.6529.1224.838.8812.29.92
Asset Turnover Ratio1.281.231.081.411.431.471.331.461.050.95
PAT to CFO Conversion(x)4-1861.251.752.251.86-2.331.5
Working Capital Days
Receivable Days63688463726660447590
Inventory Days74716128131931222455
Payable Days77627169766774675984

Auro Laboratories Ltd Stock News

Auro Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Auro Laboratories on 28-Mar-2024 16:01 is ₹161.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Auro Laboratories stood at ₹100.4.
The latest P/E ratio of Auro Laboratories as of 28-Mar-2024 16:01 is 13.96.
The latest P/B ratio of Auro Laboratories as of 28-Mar-2024 16:01 is 2.53.
The 52-week high of Auro Laboratories is ₹178.0 and the 52-week low is ₹52.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auro Laboratories is ₹55.10 ( Cr.) .

About Auro Laboratories Ltd

Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.

Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.

Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others.   Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.

Products

APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.

Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.

Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and  5-Bromo Phthalide

Milestones

1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.

1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).

2004-Company received ISO 9001:2000 certification.

2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).

2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.

Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.